CEO Executive AssistantTime management for pharma business development is one of the most consequential time allocation challenges a pharmaceutical CEO faces. Business development and M&A activity in pharma carries some of the highest financial and strategic stakes of any CEO decision domain: a poorly structured licensing deal, an overvalued acquisition, or a missed partnership opportunity can define an organization’s trajectory for a decade. At the same time, deal processes are inherently time-intensive, relationship-dependent, and difficult to fully delegate. Without a structured approach, pharma business development will expand to consume the majority of a CEO’s external-facing time, at the expense of operational leadership, investor relationships, and the pipeline oversight that sustains long-term organizational value.
This guide is designed to help pharma CEOs build a time management framework for business development that ensures appropriate CEO involvement in the highest-stakes deals, maintains a functioning deal pipeline through structured review cadences, and protects the operational leadership time that organizational health requires.
The CEO’s Role in Pharma Business Development
Separating Strategic Involvement from Operational Execution
Pharma business development operates across a wide spectrum of activity: business intelligence and competitive landscape monitoring, early-stage partnership scouting, alliance management for existing partnerships, term sheet negotiation, due diligence coordination, and deal execution. Not all of these activities require the same level of CEO involvement, and most CEOs who feel overwhelmed by business development time demands are spending executive time at the wrong points in the BD process.
The CEO’s highest-value involvement in pharma business development falls into four specific areas. First, setting the BD strategy: the therapeutic area focus, the stage preference (early versus late stage), the deal structure parameters (licensing versus acquisition), and the financial thresholds that define a deal worth pursuing. Second, relationship-building with counterpart CEOs and scientific leadership at potential partners, which requires CEO-level engagement that no BD professional can substitute for. Third, term sheet-level involvement in deals that meet the strategic and financial criteria the CEO has established. Fourth, final decision-making on any deal that requires board approval or that represents a strategic commitment above a defined financial threshold.
Everything else in the BD process, including deal scouting, conference attendance for deal origination, initial screening of inbound partnership inquiries, scientific due diligence coordination, legal and financial due diligence management, and alliance management of existing partnerships, belongs to the Head of Business Development and their team. A CEO who is involved in all of this is not leveraging the BD function. They are substituting for it.
Establishing Deal Threshold Criteria
The most important time management tool in pharma business development is a clearly documented set of deal threshold criteria that specify when CEO involvement is required. Without these criteria, every deal in the pipeline potentially justifies CEO involvement, and the BD team will use CEO time as a default resource rather than a strategic one.
Establish threshold criteria across three dimensions. Financial thresholds: the upfront payment, milestone commitment, or acquisition price above which CEO involvement in deal evaluation is required (typically in the $50 million to $100 million range for mid-size pharma, higher for large-cap organizations). Strategic thresholds: deal structures that would represent a major strategic shift, such as entering a new therapeutic area, acquiring a commercial-stage asset when the company has no existing commercial infrastructure, or structuring a co-development deal that significantly affects pipeline prioritization. Relationship thresholds: counterpart organizations where CEO-level relationship engagement is required because the deal requires CEO-to-CEO chemistry to advance, typically with major pharma, large biotech, or academic medical center partners.
Document these thresholds and share them with your Head of BD and your Chief Financial Officer. Below the thresholds, the BD team evaluates and recommends. Above the thresholds, the CEO is engaged in evaluation and decision-making. The thresholds are not permanent: review and update them annually as the company’s scale and strategic focus evolves.
Structuring the Deal Pipeline Review
The Monthly BD Pipeline Review: What Belongs and What Does Not
The monthly BD pipeline review is the cornerstone of CEO oversight of business development activity. This is a 60 to 90 minute session with your Head of BD and, depending on organizational structure, your CFO and Chief Scientific Officer. Its purpose is to give the CEO visibility into the full deal pipeline and to identify any deals approaching the threshold criteria that will require CEO involvement in the coming 30 to 60 days.
The monthly pipeline review should cover: new deals that have entered screening since the last review, the current stage of active deals being evaluated, deals where CEO involvement is anticipated in the near term and why, any deals where the BD team is recommending a pass and needs CEO concurrence, and alliance management updates on significant existing partnerships.
The monthly pipeline review is not a deal deep dive. The CEO should not be hearing the scientific rationale, the detailed term sheet economics, or the due diligence findings for every deal in the pipeline. Those are BD team responsibilities. What you need from the monthly review is a clear read on pipeline health, an early warning on deals approaching the CEO involvement threshold, and confidence that the BD team is actively managing the opportunity pipeline against the strategic and financial criteria you have established.
Your Head of BD should deliver a written pipeline dashboard 48 hours before the monthly review: one to two pages summarizing the active pipeline, stage by stage, with a clear flag for any deals that are approaching CEO involvement thresholds. A CEO who reviews this dashboard before the review session will spend the meeting time on the decisions and strategic questions that require executive judgment, not on receiving pipeline status updates that should have been read in advance.
The Deal Deep Dive: When and How
When a deal in the pipeline reaches the CEO involvement threshold, transition from pipeline review to a deal deep dive. The deal deep dive is a separate meeting, typically 90 minutes to 2 hours, structured to give the CEO the specific information needed to make or recommend a decision: the scientific and clinical rationale, the competitive landscape for the asset or technology, the deal economics and how they compare to market comps, the key risks and the BD team’s assessment of them, and the recommended deal structure.
The deal deep dive should end with a clear CEO decision or direction. If the CEO is not in a position to decide at the end of the deep dive, identify the specific additional information needed and set a follow-up timeline. A deal deep dive that ends with “let’s keep evaluating” without a specific decision timeline is inefficient for everyone involved, and it often signals that the BD team has brought the deal to CEO level before it was sufficiently developed.
Research from McKinsey & Company on pharmaceutical business development effectiveness identifies that pharma companies with disciplined CEO involvement frameworks for BD decisions significantly outperform those with inconsistent or overly broad CEO engagement. The discipline of clear thresholds and structured deep dives produces faster decisions, better deal terms, and stronger BD team performance.
Term Sheet Involvement: Getting the Level Right
CEO Involvement in Term Sheet Negotiation
Term sheet negotiation is the point in a pharma business development process that most directly benefits from CEO involvement in deals above the threshold criteria. Term sheets establish the economic and structural parameters of a deal, and the CEO’s authority to make commitments, adjust financial parameters, and navigate relationship dynamics with counterpart leadership is often decisive in moving a deal from attractive to closed.
That said, CEO involvement in term sheet negotiation should be targeted, not comprehensive. The BD team should develop the initial term sheet position and negotiate the preliminary economic parameters before CEO engagement. CEO involvement at the term sheet stage is most valuable in two specific situations. First, when the deal economics have reached a point where only CEO-level authority can approve the financial parameters being discussed. Second, when the counterpart organization has escalated the negotiation to their CEO and peer-level engagement is required to maintain deal momentum.
Outside these situations, the CEO’s role at the term sheet stage is to review and approve the BD team’s negotiating position, not to conduct the negotiation directly. A CEO who is personally handling all term sheet mechanics is substituting for their Head of BD rather than enabling them.
Managing CEO Time During Active Deal Processes
When a significant deal is in active negotiation, CEO time management requires a different approach than the steady-state pipeline review cadence. Active deal processes generate continuous decision points, counterpart relationship requirements, board communication obligations, and internal coordination demands. Without structure, an active deal can consume a CEO’s entire schedule for weeks.
Establish a deal cadence for active negotiations: a 30-minute daily check-in with your Head of BD during the peak negotiation period, a clear protocol for which deal decisions require CEO involvement and which the BD team handles independently, and a defined communication channel for board updates on deal progress. The 30-minute daily check-in replaces the constant ad hoc interruptions that an unstructured deal process generates and concentrates CEO involvement at the specific points where executive judgment is needed.
For broader guidance on managing periods of intense external engagement while maintaining operational leadership, this pharma CEO time management framework provides a useful structure for balancing BD intensity with ongoing organizational responsibilities.
Protecting Operational Leadership Time During Active BD Cycles
The Operational Leadership Risk in BD-Heavy Periods
The most significant time management risk for pharma CEOs in active business development periods is operational neglect. When a major deal is in negotiation, the gravitational pull toward deal activity is intense. Internal leadership meetings get cancelled or shortened. Direct reports find the CEO unavailable. Operational decisions that require CEO involvement queue up and slow organizational momentum.
Active BD periods create predictable operational leadership gaps unless you build explicit protection into your calendar. Before entering an active deal negotiation phase, review your operational calendar for the anticipated deal period and identify the commitments that cannot be deferred: board-scheduled meetings, investor communications, key talent decisions, and major operational reviews that have been planned well in advance. These should be treated as immovable and protected from deal schedule pressure.
The operational commitments that can flex during a deal process are the smaller-scale internal meetings, the less time-sensitive project reviews, and the non-critical stakeholder engagements. Work with your executive assistant to identify and reschedule the flexible commitments before the deal process begins, so that the deal consumes calendar white space rather than displacing organizational leadership commitments.
Delegating BD Follow-Through to the BD Team
A common time drain after a deal closes is the CEO remaining involved in post-closing integration activities, alliance launch mechanics, and partner relationship management at a level of detail that the BD team and business unit leaders should own. Define clearly with your Head of BD what post-closing activities require CEO involvement (typically: governance structure establishment, CEO-to-CEO relationship maintenance with the partner, and board-level reporting on the alliance) and what is fully owned by the BD team and relevant business unit leaders.
The CEO’s post-closing role in a licensing deal is fundamentally different from the CEO’s role during deal negotiation. Negotiation requires executive authority and relationship access that only you can provide. Post-closing integration requires operational project management and alliance management expertise that your BD team is better positioned to execute. The failure to make this transition explicitly after a deal closes results in a CEO who is perpetually involved in BD execution and never fully returns to strategic leadership cadence.
For a framework on structuring executive calendar commitments across BD and operational leadership responsibilities simultaneously, this CEO calendar structure guide provides the foundational approach for protecting strategic time across competing priorities.
Conclusion
Time management for pharma business development requires the same precision that good deal structuring requires: clear criteria, defined thresholds, structured process, and the discipline to stay at the right level of involvement at each stage. Your Head of BD and their team are professionals who perform best when they have strategic direction, clear authority below the threshold criteria, and CEO engagement that is focused, prepared, and decisive when it is activated.
The documented threshold criteria, the monthly pipeline review, the structured deal deep dive process, the targeted term sheet involvement approach, and the operational protection protocols together build the governance architecture for effective pharma business development oversight. Apply them consistently and you will find that time management for pharma business development produces both stronger deals and a CEO whose operational and strategic leadership capacity remains intact throughout the BD cycle.